State of the U.S. Market for Dental Bone Graft Substitutes and Other Biomaterials

The dental bone graft substitute and other biomaterials market includes dental bone graft substitutes (DBGS), dental growth factors, and dental barrier membranes. The DBGS market is relatively stable with an increasing shift towards allografts. Already representing the largest segment of total DBGS materials, the allograft market is expected to grow at a 5.8% compound annual growth rate (CAGR) by 2023. The most innovative market in dental biomaterials is dental growth factor technology. However, these products have been slow to make strides on the market due to their relatively high price point. As such, growth within the DBGS and other biomaterials market is predominately stimulated by growth of the dental implant market in the United States. Dental Growth Factors Continued to be limited by High Associated Costs In 2005, FDA approved the release of BioMimetic’s GEM 21S, the first growth factor matrix approved for dental use. The product has since gained traction and received CE mark approval to enter the European market in 2012. However, in comparison to the United States, there are far less commercially distributed products in other regions such as Asia and Europe. Dental growth factor products currently offered in the U.S. market are the GEM 21S, INFUSE, Osteocel, and Emdogain. Over the next several years, a number of additional growth factor combinations are expected to enter the tissue engineering product market. However, the total growth factor market is not expected...
Source: MDDI - Category: Medical Devices Authors: Tags: Materials Source Type: news